Company Gan & Lee Pharmaceuticals.

603087

CNE100003ZH1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 05/12/2025			5-day change	1st Jan Change
63.60 ^CNY	+1.92%		-0.11%	+44.22%

11-18	Gan & Lee Pharmaceuticals Europe GmbH Announces Committee for Medicinal Products for Human Use of the European Medicines Agency Recommends the Approval of Insulin Glargine Injection	CI
10-30	Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI

Business description: Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals is a China-based company mainly engaged in the research and development, production and sales of insulin analog APIs and injections. The Company's main products include insulin glargine injection Changxiulin, insulin lispro injection Suxiulin, protamine zinc recombinant insulin lispro mixed injection (25R) Suxiulin 25, Insulin Aspart Injection Ruixilin, Insulin Aspart 30 Injection Ruixilin30, Protamine Human Insulin Mixed Injection (30R) Puxilin30 and many other insulin analogs and human insulin varieties, covering three functional market segments of long-acting, rapid-acting and premixed insulin.

Number of employees: 5,245

Sales by Activity: Gan & Lee Pharmaceuticals.

Fiscal Period: December	2020	2021	2022	2023	2024
Development, Production and Sales of Insulin and Related Products	3.36B	3.61B	1.71B	2.61B	3.05B

See all business segments

Geographical breakdown of sales: Gan & Lee Pharmaceuticals.

Fiscal Period: December	2020	2021	2022	2023	2024
China	3.27B	3.36B	1.44B	2.18B	2.52B
International	92.81M	256M	276M	426M	528M

See all geographic segments

Executive Committee: Gan & Lee Pharmaceuticals.

Manager	Title	Age	Since
Kai Du CEO	Chief Executive Officer	48	19/07/2020
Cheng Sun DFI	Director of Finance/CFO	46	19/07/2020
Wei Chen PRN	Corporate Officer/Principal	45	31/12/2018
Yi Wang PRN	Corporate Officer/Principal	35	31/12/2017
Wei Qiang Song PRN	Corporate Officer/Principal	43	31/12/2004

See GAN & LEE PHARMACEUTICALS. governance

Composition of the Board of Directors: Gan & Lee Pharmaceuticals.

Director	Title	Age	Since
Zhong Ru Gan CHM	Chairman	77	16/06/1998
Kai Du BRD	Director/Board Member	48	31/12/2009
Tao Zhang CHM	Chairman	47	09/09/2021
Wei Qiang Song BRD	Director/Board Member	43	14/09/2015
Yan Qing He BRD	Director/Board Member	40	25/04/2019
Guo Jun Zheng BRD	Director/Board Member	57	25/04/2019
Jia Xin Wang BRD	Director/Board Member	32	25/04/2019
Lei Yin BRD	Director/Board Member	46	17/03/2021
Jiao Jiao BRD	Director/Board Member	37	17/03/2021
Yi Wang BRD	Director/Board Member	35	17/03/2021

Composition of the Board of Directors

Shareholders: Gan & Lee Pharmaceuticals.

Name	Equities	%	Valuation
Zhong Ru Gan 39.9 %	211,917,642	39.9 %	2 029 M ¥
Qiming Venture Partners Ltd. 5.162 %	27,414,409	5.162 %	263 M ¥
China Southern Asset Management Co., Ltd. 2.412 %	12,811,468	2.412 %	123 M ¥
China Merchants Fund Management Co., Ltd. 1.198 %	6,359,680	1.198 %	61 M ¥
Xi Ru Gan 1.172 %	6,223,276	1.172 %	60 M ¥

Name	Equities	%	Valuation
Zhong Ru Gan 72.27 %	28,508,550	72.27 %	273 M ¥
Hillhouse Investment Management Ltd. (Invest) 10.89 %	4,296,032	10.89 %	41 M ¥

List of GAN & LEE PHARMACEUTICALS. shareholders

Company details: Gan & Lee Pharmaceuticals.

Gan & Lee Pharmaceuticals Co., Ltd.

8, Nanfeng West 1st Street

101109, Beijing

http://www.ganlee.com

address Gan & Lee Pharmaceuticals.(603087)

Biopharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GAN & LEE PHARMACEUTICALS.	+1.92%	-0.11%	+38.62%	+83.87%	5.35B
REGENERON PHARMACEUTICALS, INC.	-0.61%	-7.92%	-7.67%	-3.89%	73.7B
CSL LIMITED	-0.81%	-1.18%	-34.44%	-38.79%	58.94B
UCB	+3.17%	+2.91%	+33.57%	+247.91%	54.7B
SAMSUNG BIOLOGICS CO.,LTD.	-2.32%	+64.10%	+64.10%	+64.10%	51.57B
BIOGEN INC.	-0.37%	-0.43%	+14.91%	-37.80%	26.6B
INNOVENT BIOLOGICS, INC.	-1.66%	-2.23%	+143.39%	+224.51%	20.25B
INCYTE CORPORATION	+2.05%	-1.86%	+35.04%	+24.21%	20.13B
ALTEOGEN INC.	-12.04%	-14.35%	+49.18%	+1,058.63%	16.58B
BRIDGEBIO PHARMA, INC.	-1.50%	+2.26%	+155.78%	+687.59%	14.19B
Average	-1.22%	-2.54%	+49.25%	+231.03%	34.2B
Weighted average by Cap.	-0.74%	-2.47%	+28.61%	+134.72%